Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech

Sandoz has entered a licensing agreement to acquire three biosimilar drugs from Shanghai Henlius Biotech, expanding its biosimilar portfolio and access to the Chinese biopharmaceutical innovation.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.